검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Minocycline |
Overview Company | Janssen Research & Development, LLC |
Overview Modality | ANTIBODY |
Overview Target | Rheumatoid Arthritis |
Overview Indication | Carcinoma, Non-Small-Cell Lung |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | target for personalized therapeutic strategies informed by immune profiles, through modulation of neuroinflammatory pathway |
MoA Biomarker | biomarker and modulator of therapeutic response |
PK/PD Half-life | 16 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Targeting the Redox-NF-κB/NLRP3 axis with intranasal liposomal minocycline mitigates aluminum-induced cognitive and structural deficits.. Chronic neurodegeneration is increasingly linked to redox imbalance and persistent activation of inflammatory pathways, particularly the NF-κB/NLRP3 inflammasome axis. Aluminum exposure induces oxidative stress, hippocampal inflammation, and cognitiv… |
Clinical Primary efficacy | ORR 0.2% |
Clinical ORR | 0.2% |
Clinical Result source | ClinicalTrials.gov NCT02564978 |
Clinical Data Tier / Score | A · 31 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Minocycline |
Overview Company | Janssen Research & Development, LLC |
Overview Modality | ANTIBODY |
Overview Target | Rheumatoid Arthritis |
Overview Indication | Carcinoma, Non-Small-Cell Lung |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Mechanism | target for personalized therapeutic strategies informed by immune profiles, through modulation of neuroinflammatory pathway |
MoA Biomarker | biomarker and modulator of therapeutic response |
PK/PD Half-life | 16 h |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Targeting the Redox-NF-κB/NLRP3 axis with intranasal liposomal minocycline mitigates aluminum-induced cognitive and structural deficits.. Chronic neurodegeneration is increasingly linked to redox imbalance and persistent activation of inflammatory pathways, particularly the NF-κB/NLRP3 inflammasome axis. Aluminum exposure induces oxidative stress, hippocampal inflammation, and cognitiv… |
Clinical Primary efficacy | ORR 0.2% |
Clinical ORR | 0.2% |
Clinical Result source | ClinicalTrials.gov NCT02564978 |
Clinical Data Tier / Score | A · 31 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교